117 related articles for article (PubMed ID: 32625485)
1. Scientific and technical guidance for the preparation and presentation of an application for authorisation of an infant and/or follow-on formula manufactured from protein hydrolysates.
; Turck D; Bresson JL; Burlingame B; Dean T; Fairweather-Tait S; Heinonen M; Hirsch-Ernst KI; Mangelsdorf I; McArdle HJ; Naska A; Neuhäuser-Berthold M; Nowicka G; Pentieva K; Sanz Y; Sjödin A; Stern M; Tomé D; Van Loveren H; Vinceti M; Willatts P; Fewtrell M; Przyrembel H; Titz A; Valtueña Martínez S
EFSA J; 2017 May; 15(5):e04779. PubMed ID: 32625485
[TBL] [Abstract][Full Text] [Related]
2. Scientific and technical guidance for the preparation and presentation of a dossier for evaluation of an infant and/or follow-on formula manufactured from protein hydrolysates (Revision 1).
; Turck D; Bresson JL; Burlingame B; Dean T; Fairweather-Tait S; Heinonen M; Hirsch-Ernst KI; Mangelsdorf I; McArdle HJ; Naska A; Neuhäuser-Berthold M; Nowicka G; Pentieva K; Sanz Y; Sjödin A; Stern M; Tomé D; Loveren HV; Vinceti M; Willatts P; Fewtrell M; Przyrembel H; Titz A; Martínez SV
EFSA J; 2021 Mar; 19(3):e06556. PubMed ID: 33791040
[TBL] [Abstract][Full Text] [Related]
3. Scientific Opinion on the safety and suitability for use by infants of follow-on formulae with a protein content of at least 1.6 g/100 kcal.
; Turck D; Bresson JL; Burlingame B; Dean T; Fairweather-Tait S; Heinonen M; Hirsch-Ernst KI; Mangelsdorf I; McArdle HJ; Naska A; Neuhäuser-Berthold M; Nowicka G; Pentieva K; Sanz Y; Sjödin A; Stern M; Tomé D; Van Loveren H; Vinceti M; Willatts P; Fewtrell M; Przyrembel H; Titz A; Valtueña Martínez S
EFSA J; 2017 May; 15(5):e04781. PubMed ID: 32625487
[TBL] [Abstract][Full Text] [Related]
4. Scientific and technical guidance on foods for special medical purposes in the context of Article 3 of Regulation (EU) No 609/2013.
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
EFSA J; 2021 Mar; 19(3):e06544. PubMed ID: 33791036
[TBL] [Abstract][Full Text] [Related]
5. Scientific and technical guidance for the preparation and presentation of a health claim application (Revision 2).
; Turck D; Bresson JL; Burlingame B; Dean T; Fairweather-Tait S; Heinonen M; Hirsch-Ernst KI; Mangelsdorf I; McArdle HJ; Naska A; Neuhäuser-Berthold M; Nowicka G; Pentieva K; Sanz Y; Sjödin A; Stern M; Tomé D; Van Loveren H; Vinceti M; Willatts P; Martin A; Strain JJ; Heng L; Valtueña Martínez S; Siani A
EFSA J; 2017 Jan; 15(1):e04680. PubMed ID: 32625270
[TBL] [Abstract][Full Text] [Related]
6. Guidance on the preparation and presentation of applications for exemption from mandatory labelling of food allergens and/or products thereof pursuant to Article 21 (2) of Regulation (EU) No 1169/2011.
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
EFSA J; 2021 Mar; 19(3):e06543. PubMed ID: 33791035
[TBL] [Abstract][Full Text] [Related]
7. Guidance for the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health: (Revision 1).
; Turck D; Bresson JL; Burlingame B; Dean T; Fairweather-Tait S; Heinonen M; Hirsch-Ernst KI; Mangelsdorf I; McArdle HJ; Naska A; Neuhäuser-Berthold M; Nowicka G; Pentieva K; Sanz Y; Sjödin A; Stern M; Tomé D; Van Loveren H; Vinceti M; Willatts P; Martin A; Strain JJ; Heng L; Valtueña Martínez S; Siani A
EFSA J; 2018 Jan; 16(1):e05136. PubMed ID: 32625682
[TBL] [Abstract][Full Text] [Related]
8. Guidance on the scientific requirements for health claims related to muscle function and physical performance: (Revision 1).
; Turck D; Castenmiller J; De Henauw S; Hirsch-Ernst KI; Kearney J; Knutsen HK; Maciuk A; Mangelsdorf I; McArdle HJ; Naska A; Pelaez C; Pentieva K; Thies F; Tsabouri S; Vinceti M; Bresson JL; Burlingame B; Dean T; Fairweather-Tait S; Heinonen M; Neuhäuser-Berthold M; Nowicka G; Sanz Y; Sjödin A; Stern M; Tomé D; Van Loveren H; Willatts P; Martin A; Strain JJ; Heng L; Valtueña Martínez S; Siani A
EFSA J; 2018 Oct; 16(10):e05434. PubMed ID: 32625715
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of an infant formula manufactured from a specific protein hydrolysate derived from whey protein isolate and concentrate produced by Société des Produits Nestlé S.A. in reducing the risk of developing atopic dermatitis.
; Castenmiller J; Hirsch-Ernst KI; Kearney J; Knutsen HK; Maciuk A; Mangelsdorf I; McArdle HJ; Naska A; Pelaez C; Pentieva K; Siani A; Thies F; Tsabouri S; Turck D; Vinceti M; Marchelli R; van Loveren H; Dumas C; Titz A; de Henauw S
EFSA J; 2021 Jun; 19(6):e06603. PubMed ID: 34140987
[TBL] [Abstract][Full Text] [Related]
10. Nutritional safety and suitability of a specific protein hydrolysate derived from a whey protein concentrate and used in an infant formula and follow-on formula manufactured from hydrolysed protein by FrieslandCampina Nederland B.V.
; Bohn T; Castenmiller J; de Henauw S; Hirsch-Ernst KI; Knutsen HK; Maciuk A; Mangelsdorf I; McArdle HJ; Naska A; Pentieva K; Siani A; Thies F; Tsabouri S; Vinceti M; Bresson JL; Castle L; Fewtrell M; Przyrembel H; Dumas C; Titz A; Turck D
EFSA J; 2023 Jul; 21(7):e08063. PubMed ID: 37469354
[TBL] [Abstract][Full Text] [Related]
11. General scientific guidance for stakeholders on health claim applications (Revision 1).
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
EFSA J; 2021 Mar; 19(3):e06553. PubMed ID: 33791037
[TBL] [Abstract][Full Text] [Related]
12. Nutritional safety and suitability of a specific protein hydrolysate derived from whey protein concentrate and used in an infant and follow-on formula manufactured from hydrolysed protein by Danone Trading ELN B.V.
; Castenmiller J; de Henauw S; Hirsch-Ernst KI; Kearney J; Knutsen HK; Maciuk A; Mangelsdorf I; McArdle HJ; Naska A; Pelaez C; Pentieva K; Siani A; Thies F; Tsabouri S; Vinceti M; Bresson JL; Castle L; Fewtrell M; Przyrembel H; Dumas C; Titz A; Turck D
EFSA J; 2020 Nov; 18(11):e06304. PubMed ID: 33312234
[TBL] [Abstract][Full Text] [Related]
13. Nutritional safety and suitability of a specific protein hydrolysate derived from whey protein concentrate and used in an infant and follow-on formula manufactured from hydrolysed protein by HIPP-Werk Georg Hipp OHG (dossier submitted by meyer.science GmbH).
; Bohn T; Castenmiller J; de Henauw S; Hirsch-Ernst KI; Katrine Knutsen H; Maciuk A; Mangelsdorf I; McArdle HJ; Naska A; Pelaez C; Pentieva K; Siani A; Thies F; Tsabouri S; Vinceti M; Bresson JL; Castle L; Fewtrell M; Przyrembel H; Dumas C; Titz A; Turck D
EFSA J; 2022 Mar; 20(3):e07141. PubMed ID: 35281653
[TBL] [Abstract][Full Text] [Related]
14. Scientific and technical guidance for the preparation and presentation of a health claim application (Revision 3).
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
EFSA J; 2021 Mar; 19(3):e06554. PubMed ID: 33791038
[TBL] [Abstract][Full Text] [Related]
15. NTP-CERHR expert panel report on the developmental toxicity of soy infant formula.
McCarver G; Bhatia J; Chambers C; Clarke R; Etzel R; Foster W; Hoyer P; Leeder JS; Peters JM; Rissman E; Rybak M; Sherman C; Toppari J; Turner K
Birth Defects Res B Dev Reprod Toxicol; 2011 Oct; 92(5):421-68. PubMed ID: 21948615
[TBL] [Abstract][Full Text] [Related]
16. Guidance on the preparation and submission of the notification and application for authorisation of traditional foods from third countries in the context of Regulation (EU) 2015/2283 (Revision 1).
; Turck D; Bresson JL; Burlingame B; Dean T; Fairweather-Tait S; Heinonen M; Hirsch-Ernst KI; Mangelsdorf I; McArdle HJ; Naska A; Neuhäuser-Berthold M; Nowicka G; Pentieva K; Sanz Y; Siani A; Sjödin A; Stern M; Tomé D; Vinceti M; Willatts P; Engel KH; Marchelli R; Pöting A; Poulsen M; Schlatter J; Gelbmann W; de Sesmaisons-Lecarré A; Verhagen H; van Loveren H
EFSA J; 2021 Mar; 19(3):e06557. PubMed ID: 33791041
[TBL] [Abstract][Full Text] [Related]
17. Protocol for a systematic review on health outcomes related to the age of introduction of complementary food for the scientific assessment of the appropriate age of introduction of complementary feeding into an infant's diet.
EFSA J; 2017 Aug; 15(8):e04969. PubMed ID: 32625630
[TBL] [Abstract][Full Text] [Related]
18. Guidance on the preparation and submission of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283 (Revision 1)
; Nutrition ; Nda A; Turck D; Bresson JL; Burlingame B; Dean T; Fairweather-Tait S; Heinonen M; Hirsch-Ernst KI; Mangelsdorf I; McArdle HJ; Naska A; Neuhäuser-Berthold M; Nowicka G; Pentieva K; Sanz Y; Siani A; Sjödin A; Stern M; Tomé D; Vinceti M; Willatts P; Engel KH; Marchelli R; Pöting A; Poulsen M; Salminen S; Schlatter J; Arcella D; Gelbmann W; de Sesmaisons-Lecarré A; Verhagen H; van Loveren H
EFSA J; 2021 Mar; 19(3):e06555. PubMed ID: 33791039
[TBL] [Abstract][Full Text] [Related]
19. Scientific substantiation of health claims in the EU.
Flynn A
Proc Nutr Soc; 2012 Feb; 71(1):120-6. PubMed ID: 21933455
[TBL] [Abstract][Full Text] [Related]
20. Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars.
European Food Safety Authority (EFSA)
EFSA J; 2018 Aug; 16(8):e05393. PubMed ID: 32626029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
